Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Notes Payables (2020 - 2024)

Tenax Therapeutics' Notes Payables history spans 3 years, with the latest figure at $57539.0 for Q2 2013.

  • On a quarterly basis, Notes Payables fell 8.61% to $57539.0 in Q2 2013 year-over-year; TTM through Apr 2013 was $57539.0, a 8.61% decrease, with the full-year FY2013 number at $57539.0, down 8.61% from a year prior.
  • Notes Payables hit $57539.0 in Q2 2013 for Tenax Therapeutics, down from $98657.0 in the prior quarter.
  • Over the last five years, Notes Payables for TENX hit a ceiling of $104178.0 in Q1 2012 and a floor of $7195.0 in Q4 2011.
  • Historically, Notes Payables has averaged $46504.3 across 3 years, with a median of $43295.0 in 2011.
  • Biggest five-year swings in Notes Payables: soared 45.42% in 2012 and later fell 8.61% in 2013.
  • Tracing TENX's Notes Payables over 3 years: stood at $7195.0 in 2011, then changed by 0.0% to $7195.0 in 2012, then surged by 699.71% to $57539.0 in 2013.
  • Business Quant data shows Notes Payables for TENX at $57539.0 in Q2 2013, $98657.0 in Q1 2013, and $7195.0 in Q4 2012.